Anne Wojcicki

23andMe Successfully Closes its Business Combination with VG Acquisition Corp.

Biological databases, Applied genetics, 23andMe, Branches of biology, Corporations, California, Special-purpose acquisition company, Anne Wojcicki

SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business combination.

Key Points:

SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business combination.
The transaction, which was approved on June 10, 2021 by VG Acquisition Corp.s shareholders, uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics.
23andMe was founded to revolutionize healthcare by empowering people with direct access to their DNA, said Anne Wojcicki, CEO and Co-Founder of 23andMe.
VG Acquisition Corp. was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Anne Wojcicki to Join Cazoo Board

Retrieved on:

Tuesday, April 20, 2021

View the full release here: https://www.businesswire.com/news/home/20210420005196/en/\nAnne Wojcicki to Join Cazoo Board (Photo: Business Wire)\nAnne is the CEO and Co-Founder of 23andMe, which pioneered direct-to-consumer genetic testing and has built the world\xe2\x80\x99s premier crowdsourced database of genotypic and phenotypic information to power its research into the genetic causes and potential treatments of disease.

Key Points:

View the full release here: https://www.businesswire.com/news/home/20210420005196/en/\nAnne Wojcicki to Join Cazoo Board (Photo: Business Wire)\nAnne is the CEO and Co-Founder of 23andMe, which pioneered direct-to-consumer genetic testing and has built the world\xe2\x80\x99s premier crowdsourced database of genotypic and phenotypic information to power its research into the genetic causes and potential treatments of disease.
Already the leading online car retailer in the UK, Cazoo is also Europe\xe2\x80\x99s leading car subscription player with over 6,000 subscribers across the UK, France and Germany.\nAlex Chesterman OBE, Founder & CEO of Cazoo said, \xe2\x80\x9cI am delighted that Anne will be joining the Cazoo Board once the business combination with AJAX completes.
Alex is one of the world\xe2\x80\x99s leading entrepreneurs and I am thrilled to work with his experienced team.
AJAX was founded by renowned US investor Dan Och in partnership with Glenn Fuhrman and strategic advisors including Steve Ells (founder, Chipotle), Jim McKelvey (co-founder, Square), Kevin Systrom (co-founder, Instagram) and Anne Wojcicki (co-founder, 23andMe).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005196/en/\n'

Web Summit: 23andMe CEO: Nine of 10 drugs fail medical trials

Retrieved on:

Thursday, December 3, 2020

23andMe, Wójcicki, Web Summit, Mike Schroepfer, Science and technology in the United States, Branches of biology, California, Anne Wojcicki

Wojcicki joined European Commission president Ursula von der Leyen, Facebook CTO Mike Schroepfer and tennis star Serena Williams at 100,000-attendee online conference Web Summit.

Key Points:

Wojcicki joined European Commission president Ursula von der Leyen, Facebook CTO Mike Schroepfer and tennis star Serena Williams at 100,000-attendee online conference Web Summit.
23andMe CEO Ann Wojcicki today spoke of breakthroughs her company has contributed to in COVID-19 and depression research.
Wojcicki made the remarks at the 100,000-attendee Web Summit the largest tech conference in the world.
Wojcicki said 23andMe has more than 12 million customers, of whom 80 percent have consented to take part in drug discovery research.

Web Summit: 23andMe CEO: Nine of 10 drugs fail medical trials

Retrieved on:

Thursday, December 3, 2020

23andMe, Wójcicki, Web Summit, Mike Schroepfer, Science and technology in the United States, Branches of biology, California, Anne Wojcicki

Wojcicki joined European Commission president Ursula von der Leyen, Facebook CTO Mike Schroepfer and tennis star Serena Williams at 100,000-attendee online conference Web Summit.

Key Points:

Wojcicki joined European Commission president Ursula von der Leyen, Facebook CTO Mike Schroepfer and tennis star Serena Williams at 100,000-attendee online conference Web Summit.
23andMe CEO Ann Wojcicki today spoke of breakthroughs her company has contributed to in COVID-19 and depression research.
Wojcicki made the remarks at the 100,000-attendee Web Summit the largest tech conference in the world.
Wojcicki said 23andMe has more than 12 million customers, of whom 80 percent have consented to take part in drug discovery research.

WeeCare Announces Nationwide Expansion to Provide Thousands of Children Access to a Quality Early Education

Retrieved on:

Monday, March 2, 2020

Articles, Companies, Technology, Esther Wojcicki, Wójcicki, Google, Child care, Educational technology, Anne Wojcicki, Susan Wojcicki

Esther Wojcicki, Ph.D.,renowned educator, author and advisor to WeeCare, created WeeCare's " Early Learners Program " in partnership with WeeCare's Co-founder and CEO Jessica Chang.

Key Points:

Esther Wojcicki, Ph.D.,renowned educator, author and advisor to WeeCare, created WeeCare's " Early Learners Program " in partnership with WeeCare's Co-founder and CEO Jessica Chang.
Wojcicki, one of the founders of Google for Education, is apioneer in the field of instructional technology.
philosophy to teach children compassion and empathy.Through follow-up questions available on the WeeCare app, parents can reinforce at home what their child is learning at WeeCare.
As WeeCare is providing children from all socio-economic backgrounds access to a high-quality early education, I hope to also challenge society's misconceptions around home daycare."

23andMe Offers New Genetic Report on Type 2 Diabetes

Retrieved on:

Sunday, March 10, 2019

Branches of biology, Genetics, Applied genetics, Biological databases, Bioinformatics, 23andMe, RTT, Anne Wojcicki, Diabetes mellitus

MOUNTAIN VIEW, Calif., March 10, 2019 /PRNewswire/ --23andMe, Inc., the leading personal genetics company, will begin offering a new genetic Health Predisposition report on type 2 diabetes.

Key Points:

MOUNTAIN VIEW, Calif., March 10, 2019 /PRNewswire/ --23andMe, Inc., the leading personal genetics company, will begin offering a new genetic Health Predisposition report on type 2 diabetes.
When customers learn about their genetic likelihood of developing type 2 diabetes, we believe there is an opportunity to motivate them to change their lifestyle and ultimately to help them prevent the disease," said Anne Wojcicki, CEO andCo-Founder of 23andMe.
23andMe's new Type 2 Diabetes report is different from other 23andMe health reports because it was developed and entirely validated using 23andMe research data from more than 2.5 million 23andMe customers who have opted into research.
Using this data, 23andMe scientists developed a polygenic score that drew on more than 1,000 genetic variants to calculate a customer's likelihood of developing type 2 diabetes.

23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports

Retrieved on:

Wednesday, October 31, 2018

Genetics, Biology, Health, Breast cancer, Tumor markers, Tumor suppressor genes, Biological databases, 23andMe, Genetic testing, Anne Wojcicki, Food and Drug Administration, BRCA2

With this authorization, the FDA has classified these direct-to-consumer pharmacogenetic reports as moderate risk that have special controls to ensure safety, effectiveness and accuracy.

Key Points:

With this authorization, the FDA has classified these direct-to-consumer pharmacogenetic reports as moderate risk that have special controls to ensure safety, effectiveness and accuracy.
This authorization enables 23andMe to report on numerous variants associated with pharmacogenetic response.
"We've continued to innovate through the FDA and pioneer safe, effective pathways for consumers to directly access genetic health information," said 23andMe co-founder and CEO Anne Wojcicki.
This latest FDA authorization follows several years of work by 23andMe that has led to four separate FDA de novo authorizations for direct-to-consumer genetic tests for carrier status, genetic health risk reports, select BRCA1 and BRCA2 variants and now pharmacogenetic reports.

2018 Rock Health Summit Opens with Panel Featuring DotLab CEO

Retrieved on:

Thursday, October 18, 2018

23andMe, Genetics, Anne Wojcicki, Rock Health, Bioinformatics, Biology

SAN FRANCISCO, Oct. 18, 2018 /PRNewswire/ --On Tuesday, DotLab CEO Heather Bowerman spoke on the opening panel of the 2018 Rock Health Summit .

Key Points:

SAN FRANCISCO, Oct. 18, 2018 /PRNewswire/ --On Tuesday, DotLab CEO Heather Bowerman spoke on the opening panel of the 2018 Rock Health Summit .
Rock Health is one of Silicon Valley's leading digital health venture capital funds, and the panel was moderated by Rock Health's Director of Research, Megan Zweig.
This year's Summit featured innovators such as Anne Wojcicki (Co-founder and CEO, 23andMe) and Karen DeSalvo, MD (Former Acting Assistant Secretary at the U.S. Department of Health and Human Services).
In their 2018 Digital Health Midyear Funding Review , Rock Health reports on the continued upward trajectory of venture funding for digital health, reaching $3.4 billion during the first half of 2018.